Immunotherapy achieves breakthrough result in patients with Hodgkin lymphoma

Eighty-seven percent of Hodgkin lymphoma patients who participated in an early-phase immunotherapy clinical trial experienced cancer remission, scientists report. The results provide some of the most dramatic evidence to date of the potential of therapies that increase the ability of the immune system to kill cancer cells.

http://ift.tt/1z088kU